Background In general, drug metabolism has to be considered to avoid adverse effects and ineffective therapy. In particular, chemotherapeutic drug cocktails strain drug metabolizing enzymes especially the cytochrome P450 family (CYP). Furthermore, a number of important chemotherapeutic drugs such as cyclophosphamide, ifosfamide, tamoxifen or procarbazine are administered as prodrugs and have to be activated by CYP. Therefore, the genetic variability of these enzymes should be taken into account to design appropriate therapeutic regimens to avoid inadequate drug administration, toxicity and inefficiency. Objective The aim of this work was to find drug interactions and to avoid side effects or ineffective therapy in chemotherapy. Data sources and methods Information on drug administration in the therapy of leukemia and their drug metabolism was collected from scientific literature and various web resources. We carried out an automated textmining approach. Abstracts of PubMed were filtered for relevant articles using specific keywords. Abstracts were automatically screened for antineoplastic drugs and their synonyms in combination with a set of human CYPs in title or abstract. Results We present a comprehensive analysis of over 100 common cancer treatment regimens regarding drug-drug interactions and present alternatives avoiding CYP overload. Typical concomitant medication, e.g. antiemetics or antibiotics is a preferred subject to improvement. A webtool, which allows drug cocktail optimization was developed and is publicly available on http://bioinformatics.charite.de/chemoth？erapy.
References
[1]
Ingelman-Sundberg M (2005) The human genome project and novel aspects of cytochrome P450 research. Toxicology and applied pharmacology 207: 52–56.
[2]
Angalakuditi M, Gomes J (2011) Retrospective drug utilization review: impact of pharmacist interventions on physician prescribing. ClinicoEconomics and outcomes research : CEOR 3: 105–108.
[3]
Bazargan A, Tam CS, Keating MJ (2012) Predicting survival in chronic lymphocytic leukemia. Expert review of anticancer therapy 12: 393–403.
[4]
Bates S (2010) Progress towards personalized medicine. Drug discovery today 15: 115–120.
[5]
Gardiner SJ, Begg EJ (2006) Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacological reviews 58: 521–590.
[6]
Davidsen ML, Dalhoff K, Schmiegelow K (2008) Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. Journal of pediatric hematology/oncology 30: 831–849.
[7]
Bosch TM, Meijerman I, Beijnen JH, Schellens JH (2006) Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clinical pharmacokinetics 45: 253–285.
[8]
Egbelakin A, Ferguson MJ, MacGill EA, Lehmann AS, Topletz AR, et al. (2011) Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatric blood & cancer 56: 361–367.
[9]
Patterson LH, Murray GI (2002) Tumour cytochrome P450 and drug activation. Current pharmaceutical design 8: 1335–1347.
[10]
Mehta PA, Davies SM (2004) Pharmacogenetics of acute lymphoblastic leukemia. Current opinion in hematology 11: 434–438.
[11]
Morrow PK, Serna R, Broglio K, Pusztai L, Nikoloff DM, et al. (2011) Effect of CYP2D6 polymorphisms on breast cancer recurrence. Cancer
[12]
Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, et al. (2002) The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. British journal of cancer 86: 774–778.
[13]
Lund B, Asberg A, Heyman M, Kanerva J, Harila-Saari A, et al. (2011) Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatric blood & cancer 56: 551–559.
[14]
Gor PP, Su HI, Gray RJ, Gimotty PA, Horn M, et al. (2010) Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast cancer research : BCR 12: R26.
[15]
Engelhardt MB, Mertelsmann R (2008) Das Blaue Buch: Springer. 200 p.
[16]
Nelson DR (2006) Cytochrome P450 nomenclature, 2004. Methods in molecular biology 320: 1–10.
[17]
Flockhart DA (2007) Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine
[18]
Geer LY, Marchler-Bauer A, Geer RC, Han L, He J, et al. (2010) The NCBI BioSystems database. Nucleic acids research 38: D492–496.
[19]
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic acids research 28: 235–242.
[20]
Berners-Lee T, Hendler J (2001) Publishing on the semantic web. Nature 410: 1023–1024.
[21]
Berners-Lee T, Hall W, Hendler J, Shadbolt N, Weitzner DJ (2006) Computer science. Creating a science of the Web. Science 313: 769–771.
[22]
Niwa T, Murayama N, Yamazaki H (2011) Stereoselectivity of human cytochrome p450 in metabolic and inhibitory activities. Current drug metabolism 12: 549–569.
[23]
Baumhakel M, Kasel D, Rao-Schymanski RA, Bocker R, Beckurts KT, et al. (2001) Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. International journal of clinical pharmacology and therapeutics 39: 517–528.
[24]
Chang TK, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer research 53: 5629–5637.
[25]
Chang TK, Yu L, Maurel P, Waxman DJ (1997) Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer research 57: 1946–1954.
[26]
Lindley C, Hamilton G, McCune JS, Faucette S, Shord SS, et al. (2002) The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug metabolism and disposition: the biological fate of chemicals 30: 814–822.
[27]
Roy P, Yu LJ, Crespi CL, Waxman DJ (1999) Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug metabolism and disposition: the biological fate of chemicals 27: 655–666.
[28]
Colburn DE, Giles FJ, Oladovich D, Smith JA (2004) In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology 9: 217–221.
[29]
Araya Z, Tang W, Wikvall K (2003) Hormonal regulation of the human sterol 27-hydroxylase gene CYP27A1. The Biochemical journal 372: 529–534.
[30]
Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ (1996) Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. The Journal of pharmacology and experimental therapeutics 277: 105–112.
[31]
Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, et al. (2001) Induction of CYP2C genes in human hepatocytes in primary culture. Drug metabolism and disposition: the biological fate of chemicals 29: 242–251.
[32]
Grishanov A, Kaledin VI, Zueva TV, Nekhoroshkova EK, Nikolin VP, et al. (2003) [Activity and induction of CYP2B, CYP2C, and CYP3A in tissues of cyclophosphane-sensitive and resistant neoplasms and the liver of neoplasm-carrying mice]. Biomeditsinskaia khimiia 49: 27–34.
[33]
Hukkanen J, Lassila A, Paivarinta K, Valanne S, Sarpo S, et al. (2000) Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. American journal of respiratory cell and molecular biology 22: 360–366.
[34]
Kanou M, Usui T, Ueyama H, Sato H, Ohkubo I, et al. (2004) Stimulation of transcriptional expression of human UDP-glucuronosyltransferase 1A1 by dexamethasone. Molecular biology reports 31: 151–158.
[35]
Krusekopf S, Roots I, Kleeberg U (2003) Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. European journal of pharmacology 466: 7–12.
[36]
Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, et al. (1995) Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug metabolism and disposition: the biological fate of chemicals 23: 1315–1324.
[37]
Miranda SR, Meyer SA (2007) Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 45: 871–877.
[38]
Oertle M, Muller J (1993) Two types of cytochrome P-450(11 beta) in rat adrenals: separate regulation of gene expression. Molecular and cellular endocrinology 91: 201–209.
[39]
Savas U, Hsu MH, Johnson EF (2003) Differential regulation of human CYP4A genes by peroxisome proliferators and dexamethasone. Archives of biochemistry and biophysics 409: 212–220.
[40]
Trzeciak WH, LeHoux JG, Waterman MR, Simpson ER (1993) Dexamethasone inhibits corticotropin-induced accumulation of CYP11A and CYP17 messenger RNAs in bovine adrenocortical cells. Molecular endocrinology 7: 206–213.
[41]
Vrzal R, Stejskalova L, Monostory K, Maurel P, Bachleda P, et al. (2009) Dexamethasone controls aryl hydrocarbon receptor (AhR)-mediated CYP1A1 and CYP1A2 expression and activity in primary cultures of human hepatocytes. Chemico-biological interactions 179: 288–296.
[42]
Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, et al. (2006) Selective metabolism of vincristine in vitro by CYP3A5. Drug metabolism and disposition: the biological fate of chemicals 34: 1317–1327.
[43]
Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ (1999) Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clinical pharmacology and therapeutics 66: 589–593.
[44]
Zhou-Pan XR, Seree E, Zhou XJ, Placidi M, Maurel P, et al. (1993) Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer research 53: 5121–5126.
[45]
Bell EC, Ravis WR, Chan HM, Lin YJ (2007) Lack of pharmacokinetic interaction between St. John's wort and prednisone. The Annals of pharmacotherapy 41: 1819–1824.
[46]
Ferron GM, Pyszczynski NA, Jusko WJ (1999) Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. Journal of pharmacokinetics and biopharmaceutics 27: 1–21.
[47]
Usui T, Saitoh Y, Komada F (2003) Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biological & pharmaceutical bulletin 26: 510–517.
[48]
Xia XY, Peng RX, Yu JP, Wang H, Wang J (2002) In vitro metabolic characteristics of cytochrome P-450 2A6 in Chinese liver microsomes. Acta pharmacologica Sinica 23: 471–476.
[49]
May-Manke A, Kroemer H, Hempel G, Bohnenstengel F, Hohenlochter B, et al. (1999) Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide. Cancer chemotherapy and pharmacology 44: 327–334.
[50]
Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, et al. (1993) Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochemical pharmacology 45: 853–861.
